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Abstract
Physiological studies of placebo-mediated suggestion have been recently performed beyond their
traditional clinical context of pain and analgesia. Various neurotransmitter systems and immunological
modulators have been used in successful placebo suggestions, including Dopamine, Cholecystokinin
and, most extensively, opioids. We adhered to an established conceptual framework of placebo research
and used the μ-opioid-antagonist Naloxone to test the applicability of this framework within a cognitive
domain (e.g. memory) in healthy volunteers. Healthy men (n=62, age 29, SD=9) were required to
perform a task-battery, including standardized and custom-designed memory tasks, to test short-term
recall and delayed recognition. Tasks were performed twice, before and after intravenous injection of
either NaCl (0.9%) or Naloxone (both 0.15mg/kg), in a double-blind setting. While one group was given
neutral information (S-), the other was told that it might receive a drug with suspected memory-boosting
properties (S+). Objective and subjective indexes of memory performance and salivary cortisol (as a
stress marker) were recorded during both runs and differences between groups were assessed.
Short-term memory recall, but not delayed recognition, was objectively increased after
placebo-mediated suggestion in the NaCl-group. Naloxone specifically blocked the suggestion effect
without interfering with memory performance. These results were not affected when changes in salivary
cortisol levels were considered. No reaction time changes, recorded to uncover unspecific attentional
impairment, were seen. Placebo-mediated suggestion produced a training-independent, objective and
Naloxone-sensitive increase in memory performance. These results indicate an opioid-mediated placebo
effect within a circumscribed cognitive domain in healthy volunteers.
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Abstract 
Physiological studies of placebo-mediated suggestion have been recently 
performed beyond their traditional clinical context of pain and analgesia. Various 
neurotransmitter systems and immunological modulators have been used in 
successful placebo suggestions, including Dopamine, Cholecystokinin and, most 
extensively, opioids. We adhered to an established conceptual framework of 
placebo research and used the μ-opioid antagonist Naloxone to test the 
applicability of this framework within a cognitive domain (e.g. memory) in healthy 
volunteers. Healthy men (n = 62, age 29, SD = 9) were required to perform a 
task-battery, including standardized and custom-designed memory tasks, to test 
short-term recall and delayed recognition. Tasks were performed twice, before 
and after intravenous injection of either NaCl (0.9%) or Naloxone (both 
0.15mg/kg), in a double-blind setting. While one group was given neutral 
information (S-), the other was told that it might receive a drug with suspected 
memory-boosting properties (S+). Objective and subjective indexes of memory 
performance and salivary cortisol (as a stress marker) were recorded during both 
runs and differences between groups were assessed. Short-term memory recall, 
but not delayed recognition, was objectively increased after placebo-mediated 
suggestion in the NaCl-group. Naloxone specifically blocked the suggestion 
effect without interfering with memory performance. These results were not 
affected when changes in salivary cortisol levels were considered. No reaction 
time changes, recorded to uncover unspecific attentional impairment, were seen.  
Placebo-mediated suggestion produced a training-independent, objective and 
Naloxone-sensitive increase in memory performance. These results indicate an 
  
 
opioid-mediated placebo effect within a circumscribed cognitive domain in 
healthy volunteers.  
 
Keywords: Placebo, Suggestion, Working Memory, Short-term recall, Naloxone, 
Opioids 
  
 
Introduction 
An ongoing challenge facing research on the placebo effect is how to properly 
disentangle its subjective and objective components (Harrington, 2008; 
Harrington, 1999; Moerman, 2002). Within clinical contexts in particular, 
conceptual ambiguities related to this problem often persist, hindering proper 
evaluation of standard biomedical therapeutic interventions, and presenting 
difficulties for the assessment, appreciation and harnessing of the power of 
placebo effects (Benedetti, 2009b; Frank, 1993; Kradin, 2008). (For a perspective 
on how objectivity and subjectivity have come have become interrelated in 
modern science see Daston (2007). For a review of the issues relating to 
objectivity within contemporary biomedical academia (Greene 2007; Lakoff 2006; 
Marks 1997; Relman 2007). Within the field of placebo research, endogenous 
opioids were the first neurobiological substrates consistently enlisted as a 
physiological mediator of the placebo effect – when the administration of the 
opioid-antagonist Naloxone was shown to reduce placebo-mediated analgesia 
(Levine, Gordon, and Fields, 1978). Since then, placebo research has expanded 
enormously and opioids continue to play a prominent role (Price, Finniss, and 
Benedetti, 2008; Zubieta and Stohler, 2009). For example, brain-imaging studies 
have begun to specify the role of opioids in placebo processes by localizing 
placebo-induced functional changes in opioid-signalling in the brain (Zubieta, 
Bueller, Jackson, Scott, Xu, Koeppe, Nichols, and Stohler, 2005). Such studies 
have begun to model the functional anatomy of multiple involved areas in the 
cerebral cortex, the midbrain and the basal ganglia involved during placebo-
  
 
mediated interactions (Faria, Fredrikson, and Furmark, 2008; Mayberg, Silva, 
Brannan, Tekell, Mahurin, McGinnis, and Jerabek, 2002; Wager, Scott, and 
Zubieta, 2007). They have also been able to account for endophenotypical 
functional traits that differentiate individuals showing stronger placebo responses 
from those who display weaker responses (Petrovic, Kalso, Petersson, and 
Ingvar, 2002; Scott, Stohler, Egnatuk, Wang, Koeppe, and Zubieta, 2008; 
Zubieta, Yau, Scott, and Stohler, 2006). In addition to opioids, other 
neurotransmitter systems such as Cholecystokinin, Dopamine and Serotonin 
have been implicated in placebo effects and, in some contexts, shown to interact 
with opioid-signalling (Benedetti and Amanzio, 1997; Furmark, Appel, 
Henningsson, Ahs, Faria, Linnman, Pissiota, Frans, Bani, Bettica, Pich, 
Jacobsson, Wahlstedt, Oreland, Langstrom, Eriksson, and Fredrikson, 2008; 
Scott, Stohler, Egnatuk, Wang, Koeppe, and Zubieta, 2007). 
 
Changes in opioid-signalling were shown to be relevant beyond pain modulation 
in clinical conditions such as Parkinson’s Disease, major depression and Post- 
traumatic Stress Disorder (PTSD) (Kennedy, Koeppe, Young, and Zubieta, 2006; 
Liberzon, Taylor, Phan, Britton, Fig, Bueller, Koeppe, and Zubieta, 2007; Oken, 
2008). Placebo-mediated changes in opioid-signalling were also shown in 
relation to muscular endurance (Benedetti, Pollo, and Colloca, 2007) and the 
regulation of emotions (Eippert, Bingel, Schoell, Yacubian, and Buchel, 2008; 
Petrovic, Dietrich, Fransson, Andersson, Carlsson, and Ingvar, 2005). 
 
  
 
The cognitive and emotional implications of suggestion processes have been 
investigated in social psychology and psychotherapy research in various ways, 
involving concepts like self-efficacy beliefs and the Pygmalion effect, amongst 
others (Bandura, 2001; Frank, 1993; Zimbardo and Leippe, 1991). In an 
educational context, brief, well-targeted interventions have been shown to boost 
the scholarly performance of youth at risk with remarkably long-lasting effects 
and to significantly reduce the chance of being caught in a downward spiral of 
negative stereotyping and disappointment. (Ambady, Shih, Kim and Pittinsky, 
2001; Cohen, Garcia, Purdie-Vaughns, Apfel, Brzustoski, 2009) This established 
body of work on social learning and cognition, together with more recent insights 
into placebo mechanisms from neuroscience and pharmacology (Benedetti, 
2009a; Krummenacher, Candia, Folkers, Schedlowski, and Schönbächler, 2010), 
including work on the functioning of 'cognitive enhancers' (see e.g. Volkow, 
Wang, Ma, Fowler, Wong, Jayne, Telang & Swanson, 2006), indicate the 
possibility of addressing the placebo effect within cognitive domains beyond 
those encountered in clinical environments and emotional reaction experiments.“ 
 
Recently, several studies have provided evidence that following targeted 
interventions, and with the appropriate training, at least some cognitive functions, 
including fluid intelligence (Feuerstein, 1980; Jaeggi, Buschkuehl, Jonides, and 
Perrig, 2008), attentional states (Slagter, Lutz, Greischar, Francis, Nieuwenhuis, 
Davis, and Davidson, 2007; Tang and Posner, 2009) and working memory 
capacity (Klingberg, Fernell, Olesen, Johnson, Gustafsson, Dahlstrom, Gillberg, 
  
 
Forssberg, and Westerberg, 2005).  
 
Opioid receptors are widely represented in the brain (Henriksen and Willoch, 
2008), being present in areas involved in learning, addiction and memory (Bruins 
Slot and Colpaert, 1999; McGaugh, 1989; Nestler, 2002). However, evidence for 
the direct involvement of endogenous opioid-signalling and of Naloxone in 
human memory has remained equivocal, or limited to specific contexts (Saddler, 
James, and Harington, 1985; Volavka, Dornbush, Mallya, and Cho, 1979). For 
instance, Naloxone-blockage of opioids was shown to increase memory 
performance in states of heightened emotional arousal (Katzen-Perez, Jacobs, 
Lincoln, and Ellis, 2001). Conversely, very high doses of Naloxone (2.0 mg/kg) 
were shown to produce memory impairments (Tariot, Sunderland, Weingartner, 
Murphy, Cohen, and Cohen, 1986). (For a review of opioid pharmacology 
(Gutstein and Akil 2001) 
 
The present study sought to investigate placebo effect outside clinical and 
emotional contexts, within a cognitive domain that is easily accessible to 
objective measurements. To do so, memory functions were tested in healthy 
volunteers in relation to their susceptibility to placebo-mediated suggestion. 
Objective memory performance was assessed together with concurrent 
subjective self-estimations of performance success.  
 
A double-blind experimental design was used and NaCl or Naloxone was 
  
 
administered to two groups of participants between two series of memory tasks. 
While a ‘suggestion group’ (S+) was told that it might receive a drug with 
suspected memory-boosting properties, a second control group (S-) did not 
receive such information (see Methods). Intra-individual changes in memory 
performance and subjective self-estimations of participants were recorded. To 
account for potential test-related changes in stress level, salivary cortisol was 
measured. 
 
We hypothesized that this setting would enable us to tease out objective from 
subjective effects following placebo intervention. 
 
 
  
 9
Methods 
 
Subjects  
Sixty-two healthy men (29 years, SD 9 years) were recruited using notice-board 
announcements. Prior to inclusion in the study, subjects were screened for 
normal memory capacity, using a digit span subtest from the revised Wechsler 
Adult Intelligence Scale (WAIS-R) (Wechsler, 1981), as well as for general health 
problems using an extensive health questionnaire. Exclusion criteria included the 
presence of acute or chronic illness, in particular neurological and psychiatric, 
gastrointestinal, hepatic, renal or cardiac diseases. Further exclusion criteria 
included use of medication at the time of the study, a history of drug or alcohol 
abuse, smoking >5 cigarettes per day, simultaneous participation in other 
research studies and, finally, being under 18 or over 60 years of age. Females 
were excluded from the study to avoid potential confounding factors related to 
menstrual cycle-dependent variation in endogenous opioid-activation (Craft, 
Mogil, and Aloisi, 2004) and memory performance (Farage, Osborn, and 
MacLean, 2008; Mordecai, Rubin, and Maki, 2008). All subjects had normal 
vision, or vision that had been successfully corrected. The study was approved 
by the local ethics committee and was conducted according to the Helsinki 
guidelines for the treatment of experimental subjects. All volunteers gave their 
written informed consent and were paid to participate. 
 
Study design 
Participants underwent memory testing that was carried out with a memory 
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battery comprising 7 tasks specified below. For each memory task, participants 
gave a subjective success estimation rating regarding their perceived memory 
performance and also provided a saliva probe at the end of the experiments. 
Thereafter, with the exception of an injection-free control group consisting of 12 
participants, participants received an intravenous (I.V.) injection of NaCl or 
Naloxone in a double-blind setting according to a randomization list. To ensure 
blinding of examiner and subjects, a study nurse not otherwise involved in the 
study applied the injection, which was labelled with numbers corresponding to a 
list containing the kind of substance being used; this was made accessible to the 
experimenter only after full completion of the study. After 5 minutes, the 
procedure was repeated with another memory task-battery, self-assessments 
and a saliva probe (Figure. 1). 
- Insert Figure. 1 at about here - 
 
Stimuli 
With the task-batteries, 2 sets of stimuli were presented in counterbalanced order 
before and after the I.V. injection. For each subject and task, the sequence of the 
task versions was randomly assigned to either the pre- or post-injection task- 
battery block. All tasks used were selected or constructed to be, as far as 
possible, emotionally neutral, i.e. highly arousing stimuli were deliberately 
avoided in order to minimize the probability of eliciting strong emotions and 
stress among participants. 
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The participants started all tasks by pressing a computer keyboard button. In 
each session, subjects performed a short practice run immediately before testing. 
The distance from the screen was arbitrarily set at about 80 cm. All subjects 
confirmed verbally that this distance was appropriate and did not impede normal 
vision. 
 
Multiple tasks 
For both the short-term and delayed-recall memory domains, multiple tasks were 
used in order to adjust for random lapses in concentration, unrelated to the task, 
which might arise when using a single task. For an overview of the advantages of 
multiple testing (Shackman, Sarinopoulos, Maxwell, Pizzagalli, Lavric, and 
Davidson 2006). 
 
Short-term recall tasks  
Five sets of stimuli with negligible emotional load, including words, numbers, 
symbol-strings, geometric figures and images of objects, were visually presented. 
These different sets of stimuli were prepared in order to encompass a wider 
range of elements pertaining to different memory domains (e.g. verbal, 
numerical, visual).  
Words (W): The two 15-word batteries of the Rey Recognition Test were used 
(Lezak, 1995). The words were reproduced verbally.  
Numbers (N): Two sets of 12 two-digit numbers, randomly selected from a pool 
of integers from 0 – 99, were used.  
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Strings (S): Two sets of 12 two-digit strings, consisting of one random number 
and one additional random symbol (e.g. “4 #”, “9 !”, etc.), were used.  
Images of objects (I): Twenty easily recognizable objects (e.g. a garden fence, 
sun glasses, a car, etc.) were custom-selected. These were standardized 
according to size and background to be intuitively visually distinctive. 
Geometric Figures (G): Two sets of 12 stimuli were presented, with each 
stimulus consisting of two 2-dimensional geometrical figures (e.g. a circle and a 
triangle, a line and a dot, a square and a line, etc.) from an adapted version of 
the Benton Test according to Kramer (Benton, 1973; Kramer, 1974).  
As we were not interested in the single tasks but in their average scores, task 
order in each session was as follows: W, N, S, I, G. The stimuli presented on a 
computer screen were shown in black (font size 72 for all symbols) against a 
white background. The presentation time was 2000 ms and the inter-stimulus 
intervals 1500 ms.  
 
Delayed recognition tasks: 
Two recognition tasks, one involving numbers and one comprising 
geometric figures, were presented 20 minutes after each of the respective 
recall tasks. Both recognition tasks contained a list of 20 items, where 10 
were items from the list previously presented in the short-term condition and 
10 were new. The participants were asked to press one of two buttons, 
depending on whether or not they thought the items presented had already 
been shown during the recall task 20 minutes before. No feedback was 
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given as to whether the subjects had performed correctly or incorrectly. The 
items for the delayed recognition task were first presented in the two short-
term tasks (numbers and geometric figures). The second presentation, for 
the delayed-recall tasks, occurred 20 minutes later. The procedure was 
similar in both cases: the first one (the short-term tasks and the recognition 
tasks) took place before, the second one (again short-term and recognition 
tasks) after drug injection. 
Substances 
Either Naloxone (1.5 mg/ ml) or NaCl (0.9%), both supplied by the Pharmacy of 
the Kanton Zurich, were intravenously injected with a dosage of 0.1 ml / kg body 
weight. 
 
Cortisol measurement 
Cortisol saliva samples were processed and concentrations measured as 
described by Meyer et al. (Meyer, Hauffa, Schedlowski, Pawlak, Stadler, and 
Exton, 2000). 
 
Procedure 
Placebo induction 
All subjects were informed about the experimental procedures. Participants were 
randomly distributed into 4 groups (group membership was totally unknown to 
the experimenter) according to a predefined list containing the ampoules of both 
substances labelled with numbers. Groups were as follows: NaCl S+ (n = 15, 15 
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right-handed), Naloxone S+ (n = 15, 12 right-handed, three ambidextrous), NaCl 
S- (n = 21, 17 right-handed, 4 ambidextrous; please note that this group includes 
an injection-free group, see below) and Naloxone S- (n = 11, 10 right-handed, 1 
left-handed) (S+ = suggestion, S- = suggestion-free).  Participants in the S+ 
group were told that the study was intended to investigate the memory-
enhancing properties of Naloxone. They were told that while Naloxone was an 
established substance in the context of intoxication diagnosis and treatment, 
strong indications for potential memory-related properties have come to the fore 
in recent research. The statement used to recruit the S- group was similar to the 
one used for the S+ group, except that it did not include any information 
regarding the potential cognitive effects of the tested drug (see supplementary 
material for this information in full). In addition to the written information, the 
experimenter orally expressed to the S+ group that the expectation was that 
memory-boosting properties would be elicited by the injected drug. The control 
group did not receive this information. After the experimental session, the 
participants were given full experimental debriefing. 
A control group (n = 12) received no injection at all. This was done in order to 
control for a potential placebo effect due to the injection procedure on its own. 
This data set was merged with the NaCl S- group data after it was found that 
these two groups did not statistically differ regarding their objective 
performances, subjective evaluations and stress-marker accounts (memory 
tasks, subjective assessments, cortisol changes: all p > 0.05).  
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Stimulus presentation 
All memory items were presented via a Macintosh laptop computer running 
Cedrus Superlab© Pro Version 4.0 software. 
 
Data recording  
Short-term free recall: The participants reproduced the recalled items on a paper 
sheet (numbers, strings, geometric figures and image names) or enumerated 
verbally (words) respectively. Items perfectly recalled were given full points. In 
the string and geometric tasks, half points were given for minor errors according 
to pre-established criteria (e.g. “3 #” instead of 3 *”, “6 =” instead of “6 _”, “8 %” 
instead of “8 :”). 
Delayed-recognition task: “Yes” and “No” button-responses were recorded, along 
with reaction times (RTs). All correct reaction time responses ranging from 400 to 
2000 ms were counted (no responses with reaction times between 200 and 399 
ms were found; shorter reaction times were deemed to be random responses). 
 
Subjective performance assessment 
All subjects gave a subjective performance-estimation rating on a visual 
analogue scale (0–100 mm, representing low to excellent performance) for each 
task in both sessions. At the end of the second run, an overall comparison of the 
performances in the two runs was also expressed on a VAS-scale. 
 
Data handling 
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Results of the seven single tasks were grouped according to the two 
domains: short-term recall (5 tasks: words, numbers, symbol strings, 
geometric figures, images) and delayed recognition (2 tasks: numbers and 
geometric figures). Given that the number of items varied between tasks, 
the results were normalized as a percentage of each task’s possible 
maximum score. Thereafter, the difference in performance between 
sessions (session 2 minus session 1) was computed. In order to avoid 
evaluating similar memory domains twice, and considering that task items 
were not standardized upon a large population of subjects, correlations 
among task scores were computed. Only two tasks correlated significantly 
with each other, namely numbers versus images (Spearman-Rho= 0.498, 
p<0.05). All other tasks showed correlations with Rho <0.25 and were 
statistically insignificant. Number and image scores were therefore 
averaged and further evaluated as a single task score. Thus, the average 
over the short-term tasks was therefore calculated as: Short-term-
performance = (W+S+(N+I/2)+GF)/4). 
 
Statistical Analyses 
All statistical analyses were computed using SPSS software package version 
16.0 (SPSS, Chicago, IL). Data were controlled for normal distribution and 
homogeneity of variance using a Levene's test and Kolmogorov-Smirnov test. 
For all analyses, the significance level was set at α = 5 %. Unless indicated, all 
results shown are means and standard error of the mean (SE). ANOVAs were 
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calculated based on the score differences (second run minus first run) for the 
four groups NaCl S+, Naloxone S-, NaCl S- and Naloxone S-. Post hoc 
comparisons were calculated by means of single Student's t-tests. These results 
were corrected by using a simple Bonferroni correction.  
 
Test for substance effect on subjective performance estimation  
To test for a potential substance effect in relation to the accuracy of subjective 
estimations of success, correlations were computed between the average score 
differences of objective- and subjective performance estimation. For this 
analysis, each of the two groups, NaCl and Naloxone, included the S- and S+ 
conditions. 
 
Test for subjective drug effects 
A one factorial ANOVA for the subjective drug effect was computed. To account 
for cortisol influences on subjective drug effect, an ANCOVA with cortisol as 
covariate was then computed. 
 
Accuracy of subjective performance estimation 
Objective results and subjective performance estimation were compared through 
the calculation of Spearman Rank correlations. 
 
Tests for potential confounders 
To test for potential effects of the injection procedure alone, an injection-free 
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control group was included. A separated one factorial ANOVA, comparing the 
group receiving an NaCl injection without accompanying drug-related suggestion 
with the injection-free group, was performed on the average scores of differences 
in any domain (objective and subjective evaluations: short-term recall; delayed 
recall). In addition, cortisol concentration changes were evaluated by means of a 
one factorial ANOVA assessing cortisol concentration changes (Cortisolpost minus 
Cortisolpre) for all groups receiving injection. In order to test the receptivity for 
suggestive cues during Naloxone conditions, reaction times (used as markers of 
attention shifts) were analyzed by means of ANOVAs for the average score of 
reaction time changes of NaCl and Naloxone groups (RTspost minus RTspre) 
during the delayed-recognition tasks.  
 
Correction of missing data 
Missing data were found for some subjects and were replaced by the respective 
group mean for the given task following the statistical considerations given in the 
SPSS statistical package. It is important to note that this procedure did not affect 
the results. Due to an unintended printing error on one examination sheet, data 
from a single task, the subjective evaluation of the image task, were not always 
recorded. Thus, in the subjective evaluation domain, the N-task was directly 
introduced into the calculations rather than the weighted value from N and I-tasks 
(see data handling above).   
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RESULTS 
1. Objective Memory Performance 
Short-term recall domain  
The one factorial ANOVA for the averages of the differences “second minus first 
run” (hereafter “score differences”) was significant (F (3,58) = 4.86, p = 0.004). 
After Bonferroni correction, post hoc comparisons showed a significantly higher 
memory performance score for NaCl S+ compared to the 3 other groups, 
Naloxone S+ (p = 0.047), NaCl S- (p = 0.029), and Naloxone S- (p = 0.006). (See 
Figure 2, left panel.) All other comparisons were statistically insignificant. The 
effect remained significant when cortisol-level changes were included as a 
covariate (Group (F (3, 54) = 5.086, p = 0.004). The factor Cortisol and its 
interaction with the factor Group were not significant. 
- Insert Figure. 2, 3 and 4 at about here - 
 
Delayed-recognition domain 
The one factorial ANOVA for the score differences in delayed-recognition tasks 
comprising the same 4 groups was not significant (F (3,58) = 1.56, p = 0.21) and 
remained insignificant when computing cortisol-level changes as covariate. 
 
2. Subjective Self-evaluation of performance Success 
Short-term domain 
The one factorial ANOVA for the score differences in the short-term recall tasks 
for the same four groups was significant (F (3,58) = 3.81, p = 0.015). Post hoc 
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analyses with Bonferroni corrections for multiple single comparisons showed a 
higher memory score for NaCl S+ compared to Naloxone S+ (p = 0.030) and 
NaCl S- (p = 0.045), and a weak trend when compared to Naloxone S- (p = 
0.081). All other comparisons were statistically insignificant (see Figure. 2, right 
panel). The effect remained significant when computing cortisol-level changes as 
a covariate using ANCOVA (F (3, 57) = 3.99, p = 0.012).  
 
Delayed recognition  
The one factorial ANOVA for the score differences in the delayed-recognition 
domain was not significant (F (3,58) = 0.14, p = 0.93). The ANCOVA with cortisol 
as covariate was also not significant (F (3, 57) = 0.51, p = 0.68).  
 
Accuracy of subjective performance estimation within the short-term recall 
domain 
Correlations were significant for both groups: NaCl(objective vs subjective): r = 0.60, p < 
0.01, (n = 36); and for Naloxone(objectve vs subjective): r = 0.53, p < 0.01, (n = 26). The 
difference between the two correlations was not significant (Zdiff. = 0.26, p < 
0.796 two-tailed) (Bruning and Kintz, 1997). 
  
Subjective drug effect  
The one factorial ANOVA for the score differences in subjective drug effect was 
significant (F (3,45) = 4.74, p = 0.006), even when accounting for cortisol in an 
ANCOVA (F (3, 44) = 3.92, p = 0.014). Post hoc tests with Bonferroni correction 
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showed a significantly higher score for NaCl S+ compared to the 2 suggestion-
free groups NaCl S- (p = 0.042), and Naloxone S- (p = 0.010). All other 
comparisons were statistically insignificant. 
 
- Insert Table 1 at about here – 
 
3. Potential confounders 
Injection-free control group 
The separated one factorial ANOVA comparing the NaCl S- group with the 
injection-free group was not significant for score differences in any domain 
(objective evaluations: short-term recall (F (1,19) = 0.25, p = 0.63); delayed recall 
(F(1,19) = 0.76, p = 0.40); and for the score of subjective estimation of 
performance success over the short-term recall and delayed-recall domains 
(F(1,19) = 0.06, p = 0.82).  
 
Control of baseline performance 
The baseline performance of all groups was compared (i.e. the first trials, before 
the drug injections). No significant differences were found (individual task 
comparisons and  score comparisons: all p>0.1). 
 
Cortisol concentration changes 
The univariate ANOVA assessing cortisol-concentration changes (Cortisolpost 
minus Cortisolpre) for all groups receiving injection was significant (F(5,59) = 2.39, 
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p = 0.048). However, post hoc comparisons did not survive Bonferroni 
corrections. 
 
Reaction times 
The ANOVAs for the score differences of reaction-time changes (RTspost minus 
RTspre) during the delayed-recognition tasks was statistically insignificant (F 
(5,72) = 0.46, p =0.81).  
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Discussion 
In the first part of this study we tested for effects of placebo-mediated suggestion 
on (1) memory performance and (2) subjective self-estimations of that 
performance. Between the two runs of memory tasks we administered an 
intravenous injection of a placebo substance (0.9%, 0.15mg/kg). While one group 
of volunteers was told that the injected substance might produce a memory-
boosting effect (S+), the other (S-) received only drug-related information 
unrelated to potential memory effects. When comparing memory performance 
scores between the runs, we found a significant increase in memory performance 
for short-term recall tasks in the S+ group, but not so in the S- group. This effect 
was not seen in delayed-recognition tasks.  
 
After completing the tasks, the participants’ estimations of performance success 
were assessed using a separate VAS for every individual task. Subjective 
estimations agreed with objective performance scores; compared to those in the 
S- groups, the participants in the S+ groups estimated their performance success 
as being higher in the short-term memory tasks, but similar in the delayed-
recognition tasks. 
  
All in all, these results show that short-term recall performance was susceptible 
to placebo-mediated suggestion: performance was objectively enhanced and not 
just subjectively considered to have increased. This increase in performance 
occurred instantaneously, within minutes of the injection.  
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Many studies have highlighted suggestion-related qualitative changes in memory 
content resulting in, for example, memory distortion and ‘false’ memories 
(Schacter and Slotnick, 2004; Wade, Sharman, Garry, Memon, Mazzoni, 
Merckelbach, and Loftus, 2007). In addition, other studies have shown that the 
cognitive capacities within some memory domains may be increased or 
preserved over time through specific training regimes (Jaeggi et al. 2008; 
Klingberg et al. 2005) or modulated through hypnosis (Mendelsohn, Chalamish, 
Solomonovich, and Dudai, 2008). The present study extends these findings and 
shows a training-independent, quantitative boosting effect of placebo-mediated 
suggestion in a circumscribed memory domain that was objectively observed. 
 
In the second part of this study we tested the role of μ-opioid processing on 
placebo-mediated suggestion and this time administered the μ-opioid-antagonist 
Naloxone as a placebo substance. After injecting either Naloxone or NaCl in a 
double-blind setting, we found that in the S- groups, objective and subjective 
evaluations of memory performance were similar in all memory domains. In the 
S+ group, however, we found that contrary to the NaCl-condition, neither 
objective short-term memory scores nor self-estimations of these scores 
increased under Naloxone. In the delayed-recognition domain, objective and 
subjective scores were similar in all four groups. 
 
While Naloxone failed to produce an inherent effect in the absence of suggestion, 
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the suggestion-related increase in performance measured in the NaCl-group was 
specifically blocked when Naloxone was administered to the S+ group. These 
results indicate that the placebo effect within the short-term recall domain was 
opioid mediated.  
 
We can only speculate about the anatomical pathways through which opioid 
signalling may fascilitate suggestive effects on cognition. Obvious candidates 
include the ventral striatum, the amygdala, the insular and anterior cingular 
cortices and possibly other structures where the opioid system interacts with 
dopaminergic neurotransmission (e.g. Zubieta & Stohler, 2009). The interactions 
may operate via influences on valence processing and/ or more directly on 
(working-) memory-related pathways 
 
Several potential confounders were considered in this study, including (1) stress, 
(2) drug-induced emotional blurring and (3) unspecific drug-related cognitive 
effects potentially affecting attention. In the following section, these factors will be 
discussed separately. 
 
Stress 
Different levels of emotional strain elicited during test situations may affect test 
performance. For instance, acute stress levels, as measured by means of 
salivary cortisol-concentration changes, have been shown in some studies to 
correlate with decreased performance in memory tasks in healthy volunteers 
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(Kuhlmann, Piel, and Wolf, 2005; Wolf, Schommer, Hellhammer, McEwen, and 
Kirschbaum, 2001). In other studies, ‘inverted u-shaped’ dose-response effects 
of stress hormones in some brain areas such as the CA1 area of the 
hippocampus have been reported (Joels, 2006). It therefore seems conceivable 
that a placebo-mediated increase in memory performance may result from a 
comforting effect of the suggestion used and as a result of reduced stress. 
However, salivary cortisol-concentration changes in the course of the experiment 
were similar across all groups, and the inclusion of pre-to-post differences in 
individual cortisol concentration as a covariate in the statistical models did not 
change these results. We conclude that the experimental situation per se did not 
elicit substantial stress reactions among volunteers. Consequently, we firmly 
believe that neither stress nor stress alleviation contributed to the present 
findings.  
 
Drug-induced emotional blurring  
Although studies investigating the impact of Naloxone on emotion have not found 
significant effects at the timescales and substance concentration levels 
investigated in the present study (0.15 mg/kg), some dysphoric effects have been 
described at higher doses (0.2 mg/kg). In addition, increased tension- and 
confusion-scores have been reported (although at later times, several hours after 
injection) (Grevert and Goldstein, 1978; Martin del Campo, Dowson, Herbert, and 
Paykel, 1994; Tariot et al., 1986). Therefore, the Naloxone effect may have been 
the result of drug-induced emotional blurring. If this were the case, such an effect 
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would reduce volunteers’ susceptibility to the suggestive intervention. We used 
correlations to compare scores of subjective estimation of performance success 
with objective scores under the action of both substances. We could not find any 
substance effects. In particular, we did not see any changes in accuracy of self-
estimation under Naloxone, which clearly goes against an emotional blurring-
effect of Naloxone as an explanatory factor for our results.  
 
Drug-related unspecific cognitive effects  
It could be argued that a Naloxone-triggered effect on alertness may have 
compromised attention among participants. It is known that attention and short-
term memory processing have partially overlapping neuroanatomical substrates 
(Awh, Vogel, and Oh, 2006; Collette and Van der Linden, 2002; LaBar, Gitelman, 
Parrish, and Mesulam, 1999). While no differences were found between the 
NaCl- and Naloxone groups in the S- condition, it is still possible that Naloxone 
may have reduced the receptivity for suggestive cues. However, reaction-time 
comparisons of correct responses in the delayed-recognition tasks (used as 
markers of attention shifts) were not significant in any of the investigated groups, 
something clearly arguing against a possible substance effect compromising 
attention. 
 
Study limitations 
Our task battery assessed a limited spectrum of memory functions, which clearly 
precludes statements regarding other subsets of potentially affected memory 
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functions. Secondly, we did not use questionnaires to assess emotional states 
and therefore had to rely on previous findings published in the literature which 
suggest that Naloxone does not induce substantial emotional effects at low 
doses within the first hour after injection (Grevert and Goldstein 1978; Martin del 
Campo et al. 1994).  
 
Over the last three decades, the role of opioid-signalling for placebo-mediated 
suggestion has been firmly established in diverse contexts ranging from pain to 
motor and mental disorders and emotions (Benedetti, Pollo, and Colloca, 2007; 
Eippert et al., 2008; Kennedy et al., 2006; Liberzon et al., 2007; Oken, 2008; 
Petrovic et al., 2005).  
 
Our data demonstrate the objective susceptibility of a cognitive domain to 
placebo-mediated suggestion. That susceptibility, manifesting as increase in 
memory performance, was specifically blocked by the μ-opioid-antagonist 
Naloxone. Naloxone did not provoke any other interference with cognitive 
function, be it objectively or subjectively. The present data indicate that μ-opioid 
signalling within an emotionally “neutral” context does not interfere with the 
processing of the cognitive tasks used per se. However, it does interact with 
placebo-mediated suggestion, possibly triggering auxiliary processes that lead to 
increased cognitive performance. We provide evidence that the reported results 
were independent of stress-related processes.  
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We conclude that the scope of μ-opioid-dependent, placebo-mediated suggestive 
processes appears to be broader than usually considered and can also play a 
role in the modulation of cognitive functions (such as short-term memory 
performance in healthy volunteers). Most importantly, our data provide objective 
evidence for placebo-mediated suggestion. 
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Legends to Figures and Tables 
 
Figure 1: Study design:  
M tasks = memory tasks; SEP = subjective estimation of performance; SEDE = 
subjective estimation of drug effect 
 
 
Figure 2:  
Objective performance (left panel) Higher gain in short-term memory span for the 
NaCl S+ group as compared to the other groups (all p< 0.05). Subjective 
estimation (right panel) Higher increase in self-assessment scores in the short-
term memory domain for the NaCl S+ group as compared to the groups NaCl S- 
and Nalox S+ (p< 0.05)  
 
Figure 3:  
Objective memory performance results are illustrated for the individual tasks, 
showing the suggestion effect (3a) and the substance effect (3b). (* = p<0.05) 
 
Figure 4:  
Subjective performance estimations are illustrated, showing suggestion effect 
(4a) and the substance effect (4b). (* = p<0.05). Please note that subjective 
'Image'-task data is missing due to a technical error (see 'Correction of missing 
data', in the last part of the methods section). 
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Table 1:  
Results for pre and post-injection trials. The objective performance is depicted in 
the upper panel. Depicted are the individual trials as mean % score with the 
corresponding SE. Subjective success, as estimated on a visual analogue scale 
(VAS), is depicted in the lower panel. Values are presented as means and SE of 
VAS improvement in %. Post = post injection, pre = pre injection. ‘Medication-
effect’ corresponds to the subjective score for the overall effect of the drug. 
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Supplementary material 
Group instructions  
Suggestion group (S+) 
Study goals  
The goal of the present study is the assessment of the influence of Naloxone on 
memory function. Naloxone is a substance commonly used for diagnosis and 
treatment in cases of suspected overdose following the use of intoxicants 
(opioids). Some studies on the effects of Naloxone on memory function have 
been carried out. The results of these studies revealed a strong enhancement of 
memory in patients suffering from impaired brain function. Nevertheless, studies 
on healthy volunteers are still required. Consequently, we are interested in the 
further assessment of the positive memory effect of Naloxone when using a 
therapeutic dosage of (0.15 mg/kg) in healthy volunteers. In so doing, we aim to 
obtain new insights into the role of Naloxone within a cognitive setting free of 
pain. 
 
Suggestion-free group (S-) 
Study goals 
The goal of the present study is the assessment of the influence of Naloxone on 
memory function. Naloxone is a substance commonly used for diagnosis and 
treatment in cases of suspected overdosage following the use of intoxicants 
(opioids). Some studies on the effects of Naloxone on memory function have 
been carried out. The results of these studies have been contradictory (positive, 
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negative or no effects were reported) and no further studies have been carried 
out. Consequently, we are interested in the further assessment of the effects of 
Naloxone when using a therapeutic dosage of (0.15 mg/kg). In this way, we aim 
to obtain new insights into the role of Naloxone within a cognitive setting free of 
pain. 
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Research Highlights 
 
- Short-term memory recall is objectively increased after placebo-mediated suggestion. 
 
- Naloxone specifically blocks the suggestion effect without interfering with memory 
performance. 
 
- These results indicate an opioid-mediated placebo effect within a circumscribed cognitive 
domain. 
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